FDA reverses decades of guidance on hormone therapy for menopause

FDA reverses decades of guidance on hormone therapy for menopause

  • Höfundur
  • Episode
      1775
  • Published
      11 nov. 2025
  • Útgefandi
0 Umsagnir
0
Episode
1775 of 1783
Lengd
14Mín.
Tungumál
enska
Gerð
Flokkur
Óskáldað efni

The FDA is removing the black box warning on estrogen therapy after two decades. Should it?

Women who want to use estrogen to treat menopause symptoms often face a difficult choice.

That’s because those hormone treatments contain a “black-box warning.”

The Food and Drug Administration uses black box warnings to indicate a medication has potentially life threatening side effects.

In the case of estrogen for menopause symptoms, an increased risk of endometrial cancer, cardiovascular disorders, dementia and breast cancer.

Well those warnings are going away.

For sponsor-free episodes of Consider This, sign up for Consider This+ via Apple Podcasts or at plus.npr.org. Email us at considerthis@npr.org.

This episode was produced by Mia Venkat and Erika Ryan. It was edited by Courtney Dorning and Scott Hensley.

Our executive producer is Sami Yenigun.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy


Hlustaðu og lestu

Stígðu inn í heim af óteljandi sögum

  • Lestu og hlustaðu eins mikið og þú vilt
  • Þúsundir titla
  • Getur sagt upp hvenær sem er
  • Engin skuldbinding
Prófa frítt
is Device Banner Block 894x1036
Cover for FDA reverses decades of guidance on hormone therapy for menopause

Other podcasts you might like ...